{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalComment":"Cochran-Mantel-Haenszel (CMH) test stratified by age (18 - \\< 75, ≥ 75) and cytogenetic risk (intermediate, poor).","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.1","upperLimit":"25.2","value":"17.9"},{"groupId":"OG001","lowerLimit":"33.1","upperLimit":"44.7","value":"38.8"},{"groupId":"OG002","lowerLimit":"26.2","upperLimit":"87.8","value":"60.0"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.4","upperLimit":"17.3","value":"11.0"},{"groupId":"OG001","lowerLimit":"22.8","upperLimit":"33.6","value":"28.0"},{"groupId":"OG002","lowerLimit":"2.5","upperLimit":"55.6","value":"20.0"}]}],"title":"CRi"}],"denoms":[{"counts":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"286"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"CR and CRi was calculated based on current International Working Group (IWG) criteria. CR is defined as absolute neutrophil count \\>10\\^3/ microliter (mcL), platelets \\>10\\^5/mcL, red cell transfusion independence, and bone marrow with \\<5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of ≤10\\^3/mcL or platelets ≤10\\^5/mcL. Percentages are rounded off to whole number at the nearest decimal.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received venetoclax-matching placebo, orally, QD, from Day 1 to Day 28 of each 28 day cycle along with azacitidine 75 mg/m\\^2, SC or IV, QD for 7 days from Day 1 of each 28-day cycle until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation (whichever occurred first).","id":"OG000","title":"Group 2: Placebo + Azacitidine 75 mg/m^2"},{"description":"Participants received venetoclax 100 mg, once orally, on Day 1 of Cycle 1 followed by venetoclax 200 mg, once orally, on Day 2 of Cycle 1 and venetoclax 400 mg, orally, QD, from Day 3 to Day 28 of each 28-day cycle along with azacitidine 75 mg/m\\^2, SC or IV, QD for 7 days from Day 1 of each 28-day cycle until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation (whichever occurred first).","id":"OG001","title":"Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2"},{"description":"Participants received venetoclax 400 mg, orally, QD, from Day 1 to Day 28 of each 28 day cycle along with azacitidine 75 mg/m\\^2, SC, QD for 7 days from Day 1 of each 28-day cycle until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation (whichever occurred first).","id":"OG002","title":"Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^2"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set included all Group 2 participants randomized by IVRS/IWRS (exclude the open-label China safety cohort). Open-Label China Safety Cohort included participants who received at least one dose of venetoclax. Data is reported for Group 2 and Open-label China Cohort.","reportingStatus":"POSTED","timeFrame":"From the study start up to death (up to approximately 4.8 years; data cut-off date: 1 December 2021)","title":"Percentage of Participants With Complete Remission (CR) and Complete Remission With Incomplete Marrow Recovery (CRi)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}